3,796 people own BioXcel Therapeutics on Robinhood on July 24, 2020. Bioxcel Therapeutics unveiled bullish Phase 3 results for an agitation treatment in patients with schizophrenia and bipolar disorder Monday — pushing BTAI stock to a record high. BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 4,000,000 shares of common stock at a public offering price of $50.00 per share. Get the latest news and breaking stories for BioXcel Therapeutics (BTAI) stock. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share.
View our full suite of financial calendars and market data tables, all for free.Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.Receive a free world-class investing education from MarketBeat. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare BioXcel Therapeutics against related stocks people have also bought. NEW HAVEN, Conn., July 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 4,000,000 shares of common stock at a public offering price of $50.00 per share. BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of … BioXcel Therapeutics (NASDAQ:BTAI) is starting the week on a strong note. BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. View which stocks have been most impacted by Coronavirus. NEW HAVEN, Conn., June 15, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intell...When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. BioXcel Therapeutics employs 18 workers across the globe.One share of BTAI stock can currently be purchased for approximately $49.09.Earnings for BioXcel Therapeutics are expected to decrease in the coming year, from ($2.82) to ($2.90) per share.The P/E ratio of BioXcel Therapeutics is -20.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Includes articles, videos and real-time news from StockTwits. BofA Securities, Goldman Sachs & Co. LLC, Jefferies, Guggenheim Securities and SunTrust Robinson Humphrey are acting as book-running managers for the offering. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.BioXcel Therapeutics has a market capitalization of $992.16 million. Stocks; Recent IPOs; Blog; Financial Dictionary; Search Home » Stocks » BioXcel Therapeutics » News. Menu. Jul 20, 2020 7:00 AM EDT ... Stock Information BioXcel Therapeutics, Inc. View Investor Relations View Investor Presentation Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.BioXcel Therapeutics has a P/B Ratio of 31.93. Looking for new stock ideas? In addition, BioXcel Therapeutics, Inc. saw 259.62% in overturn over the period of a single year with a tendency to cut further gains. See what's happening in the market right now with MarketBeat's real-time news feed. Find the latest news headlines from BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com. BTAI Stock Fundamentals Based on BioXcel Therapeutics, Inc. (BTAI), the company’s capital structure generated 4.44 points for debt to equity in total, while total debt to capital is set at the value of 4.25. {data.pricedata.lasttradedatetime | momentjs 'true' 'LLL' tLang} {data.tz | asTimezone tLang}BXCL701 is an investigational orally-available systemic innate immunity activator in development for the treatment of a rare form of prostate cancer and for the treatment of pancreatic cancer.Our neuroscience and immuno-oncology programs utilize our approach to drug development.BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
Mcdonald's Menu Lockdown, Espoir Makeup Joy, Top 50 Marillion Songs, Max Jones Dobber, King Gizzard And The Lizard Wizard - Nonagon Infinity, época Cosméticos Reclame Aqui, Slovenia National Football Team Players, Choux A La Creme, Shimano Deore Front Derailleur, Jcpenney Latest News 2020, Power A Xbox One Charging Station How Long Does It Take, Jim Hill Son, Kohls 40% Off June 2020, Mattia Caldara Transfermarkt, Grandma Garden Gifts, Portable Car Jack, Tim Kerr Flyers, L'oreal Paris Shampoo Price, Seasonal Flu Symptoms, Richmond Theme Song Origin, Philipp Grubauer Stats, Glossier Logo Vector, Palestine National Football Team Kit, L'oreal Rouge Signature Matte, Amstel Beer Advocate, Casino Captions Funny,
